Tag: Takeda

Takeda held the grand opening of its Global Headquarters in Tokyo

takeda hq tokyo
Takeda Pharmaceutical Company Limited held the grand opening of Takeda Global Headquarters in Tokyo, Japan. The building, completed in March 2018, will serve as Takeda's head office for its operations worldwide.

Takeda produced three pilot batches of Actovegin as part of drug labeling project

takeda
Three pilot batches of Actovegin in the total amount of more than 40 thousand packages were produced under the drug labeling project involving the application of special 2D code.

Thermo Fisher signed new agreements with Daiichi Sankyo and Takeda

thermo-fisher
Thermo Fisher Scientific announced it has signed new agreements with Daiichi Sankyo and Takeda Pharmaceuticals designed to expand the clinical utility of Oncomine Dx Target Test in support of clinical trials and drug development.

Takeda will buy Shire for $64 billion

takeda
Japanese drugmaker Takeda has reached a tentative agreement to buy Ireland-based Shire for $64 billion in one of the biggest pharma deals to date.

Takeda Russia launches Ixazomib for treatment of multiple myeloma

Takeda Russia
Ixazomib is supplied as capsules and indicated in combination with lenalidomide and dexamethasone for patients with multiple myeloma who received at least one line of prior therapy.

Takeda sells worldwide rights for a genetic disorder drug to Rhythm Pharma

takeda
Rhythm Pharmaceuticals, a biopharmaceutical company, announced that it has acquired exclusive, worldwide rights from Takeda Pharmaceutical Company to develop and commercialize a rare genetic disorder drug.

First allogeneic stem cell therapy received approval in EU

stem cells
TiGenix NV and Takeda announced that the European Commission (EC) has approved Alofisel, previously Cx601, for the treatment of complex perianal fistulas in adult patients with nonactive/mildly active luminal Crohn’s disease.

Takeda Russia launches a combined sugar-lowering drug

takeda
Takeda, a pharmaceutical company, has developed an innovative sugar-lowering drug that is a combination of alogliptin and metformin. The representatives of the company announced that the drug was launched in the Russian market.

Takeda Russia continues strategic development of its oncology area

takeda
In the near future, the company will localize the manufacturing of several innovative products in Russia. The transfer of manufacturing to Russia will increase the availability of the drug and contribute to reducing its price.

Takeda buys a range of OTC medicines from Unipharm

takeda
Takeda Pharmaceutical Company Limited announced the signing of a framework agreement to acquire a range of over-the-counter medicines and food supplements from Unipharm Inc.

Takeda intends to buy Belgian biopharmaceutical startup

takeda
Takeda announced its intention to acquire TiGenix, a biopharmaceutical company developing novel stem cell therapies for serious medical conditions

Takeda and Portal Instruments develop needle-free drug delivery device

takeda
Takeda Pharmaceutical Company and Portal Instruments today announced a collaboration to develop and commercialize needle-free drug delivery device

Takeda is celebrating the fifth anniversary of its plant in Yaroslavl

takeda-yaroslavl
Takeda Pharmaceuticals LLC (Takeda Russia) is celebrating the fifth anniversary of its plant in Yaroslavl

Takeda localizes the manufacturing of cancer drug at Pharmstandard-UfaVITA

UfaVita Factory
Takeda Pharmaceuticals LLC and Pharmstandard JSC announced the start of their cooperation to localize the manufacturing of brentuximab vedotin

Takeda and Noile-Immune Biotech to collaborate on CAR-T cell therapy

takeda
Takeda Pharmaceutical Company Limited and Noile-Immune Biotech Inc. announced that they have entered into a collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T)

AstraZeneca and Takeda will develop Parkinson’s disease drug

Parkinsons disease
AstraZeneca and Takeda Pharmaceutical Company Limited today announced that they have entered an agreement to jointly develop and commercialise MEDI1341